Daniel Lynch, Director at SpringWorks Therapeutics, Inc. (SWTX), sold 284,400 shares at $53.23 ($15.4M) on 2025-02-10, disclosed to the SEC on 2025-02-12.
Scheduled sale ($15.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $53.23 | 69,766 | $3.7M | 24.1% |
| 2 | $53.23 | 69,766 | $3.7M | 24.1% |
| 3 | $54.88 | 39,634 | $2.2M | 14.1% |
| 4 | $54.88 | 39,634 | $2.2M | 14.1% |
| 5 | $55.51 | 65,600 | $3.6M | 23.6% |
| Total | $54.22 avg | 284,400 |
| $15.4M |
| 100% |
| Filing → |
| BPMC | SELL | 2018-02-16 | $1.0M | — | Filing → |
| BPMC | SELL | 2018-02-14 | $2.6M | — | Filing → |
| BPMC | SELL | 2017-11-17 | $420K | — | Filing → |